Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03698994
Title	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	rhabdoid cancer non-Hodgkin lymphoma histiocytic and dendritic cell cancer osteosarcoma germ cell cancer neuroblastoma high grade glioma medulloblastoma sarcoma Ewing sarcoma brain ependymoma Advanced Solid Tumor central nervous system cancer hepatoblastoma rhabdomyosarcoma neuroectodermal tumor nephroblastoma
Therapies	Ulixertinib
Age Groups:	child \| adult
Covered Countries	USA